Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management

Prostate Cancers Clinical Trial

— ProsPERo  

Official title:

Prospective Evaluation of 68Ga-PSMA-ligand PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02810886
• Other study ID #: IJB-PROS-PROSPERO-2016
• Status: Withdrawn
• Phase: Phase 2
• First received: June 20, 2016
• Last updated: August 21, 2017
• Start date: October 2016
• Est. completion date: January 20, 2017

Study information

• Verified date: August 2017
• Source: Jules Bordet Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single arm, phase II exploratory trial to prospectively evaluate the impact of 68Ga-PSMA-PET/CT on the therapeutic management of patients with biological recurrent prostate cancer and negative, equivocal or oligometastatic disease after routine imaging diagnostic work-up.

Description:

68Ga-PSMA-ligand PET-CT is a recently developed molecular imaging technique. It is based on the prostate specific membrane antigen (PSMA), a transmembrane protein with a large extracellular domain which is over-expressed on prostate cancer cells surface. Initial experiments used a ligand to the extracellular epitope of PSMA and labelled it with the isotope 68Ga, a positron emitter (68Ga-PSMA-HBED-CC) 5.

Recently published data based on more than 300 patients show recurrence detection rates and tumour to background ratios higher than choline PET-CT, even at low Prostate Specific Antigen (PSA) levels (sensitivity of 70% in PSA<2ng/ml) 6,7. False-positive PSMA findings are not yet reported.

The therapeutic management of biochemical recurrence in prostate cancer depends on the localisation and the extent of the recurrent disease.

In this study, the hypothesis is that 68Ga-PSMA-ligand PET-CT, through its high diagnostic accuracy has a significant impact on the therapeutic management of patients with biochemical recurrence.

Primary objective:

To prospectively evaluate the impact of PSMA-PET/CT on the therapeutic management of patients with biological recurrent prostate cancer and negative, equivocal or oligometastatic disease after routine imaging diagnostic work-up.

The treatment management decision will be recorded at the urologic tumor board (UTB) before and after the PSMA-PET/CT result. Rate of decision change will be calculated.

Secondary objective(s)

1. To compare detection rates of PSMA PET/CT and Routine Imaging Workup

2. To search for a predictor of a positive PET scan

3. To assess diagnostic value of PSMA-PET/CT

4. To assess PSA response after targeted treatment for oligometastatic disease.

5. To evaluate the delay to start of Androgen Deprivation Therapy (ADT) from the UTB decision.

6. To evaluate the time to PSA progression.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 20, 2017
• Est. primary completion date: January 20, 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years old.

• Histologically-proven prostate adenocarcinoma.

• Biochemical recurrence (BCR) after local treatment with radical curative intent based on PSA values 1:

• Following Radical Prostatectomy +/- Radiotherapy: a serum PSA increase confirmed by a second PSA measurement higher than the first one with a value of 0.2 ng/mL or more within minimum of one week.

• Following primary Radiotherapy: PSA value of 2 ng/ml above the nadir.

• A continued rise in PSA level despite treatment with curative intent.

• Patients with negative, inconclusive or oligometastatic disease on the Routine Imaging Workup and susceptible to be treated with curative radical intent (salvage treatment).

• Routing Imaging Workup exams are accepted when performed within 1 month before PSMA-PET/CT (this includes WB-MRI, prostatic/pelvic MRI, and/or Bone Scintigraphy).

• Patient treatment strategy based on routine diagnostic work-up needs to be recorded after discussion at the Urologic Tumor Board and available before the PSMA PET/CT.

• ECOG performance status = 2

• Signed informed consent prior to any study related procedure.

Exclusion Criteria:

• Previous malignancy other than Prostate Cancer (except basocellular or squamous cell skin cancer).

• Patients treated with palliative chemotherapy or new hormonal therapies like Abiraterone/Enzalutamide.

• PSA rise while on active treatment (LHRH-agonist, LHRH-antagonist, anti-androgen, maximal androgen blockade, oestrogen). A minimal time window of 1 month is required.

• Medical castration with Testosterone < 50 ng/dl (1.7 nmol/L).

• Metastatic patients before inclusion not considered for targeted therapy.

• Previous treatment with isotopes (Radium, Samarium, Strontium, etc.)

• All medical conditions that might interfere with the correct performance of imaging scans.

• Known allergy/sensitivity to 68Ga or HBED-CC coupled substance, or any of the ingredient(s) or excipient(s) of the study medication(s)

Related Conditions & MeSH terms

• Prostate Cancers
• Prostatic Neoplasms
• Recurrence

Intervention

Drug:
• 68Ga-(HBED-CC)-PSMA
68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jules Bordet Institute

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in treatment management are defined as: • Shift to a different therapeutic strategy • Modification of the initial therapeutic strategy • No changes		2 months
Secondary	Number of positive scans	PSMA only positive; Routine Imaging only positive; Positive in both	2 months
Secondary	Correlation of positivity with:	PSA value at the time of imaging; PSA doubling time; Gleason score	2 months
Secondary	Reference diagnosis	Histology when available.; Normalisation of PSA level after ablative therapy.; Morphological and/or biochemical evolution when no target treatment is given.	6 months
Secondary	A confirmed PSA response is defined as = 30% reduction of the blood level, compared to the baseline value, confirmed by a second PSA value 4 or more weeks later. PSA responses will be evaluated at for up to 6 months		6 months
Secondary	Androgen Deprivation Therapy (ADT) free survival: time from final Urologic Tumour Board treatment decision to start of ADT treatment during the follow up period of 6 months		6 months
Secondary	Time to prostate specific antigen (PSA) progression according to Prostate Cancer Clinical Trials Working Group criteria	In case of decline from baseline: record time from final Urulogic Tumor Board treatment decision to first PSA increase that is =25% and = 2 ng/ml above the nadir OR that is =25% above the pretreatment PSA value and which is confirmed by a second value 3 or more weeks later.; In case of no decline from baseline: PSA increase that is =25% and = 2 ng/ml after 3 months if baseline PSA is =2 ng/ml. PSA increase that is =25% after 3 months if baseline PSA is < 2 ng/ml.	3 months